Clinical evaluation of azithromycin sequential therapy in the treatment of 138 patients with community-acquired pneumonia

黄海辉,吴菊芳,张婴元,修清玉,周新,黄绍光,刘又宁,周乐,汪复

DOI: https://doi.org/10.3321/j.issn:1009-7708.2004.05.001

2004-01-01

Abstract:Objective: To evaluate the efficacy and safety of injectable azithromycin in the treatment of community-acquired pneumonia. Methods:In this multicenter, open-labeled randomized comparative study, patients with community-acquired pneumonia were allocated randomly to azithromycin monotherapy group or cefuroxime with or without erythromycin ethylsuccinate group. Results:(1) The clinical efficacy rates (azithromycin vs cefuroxime with or without erythromycin ethylsuccinate) were 88.9% (56/63) vs 92.2% (59/64), the clinical cure rates were 79.4% (50/63) vs 65.6%(42/64). There was no statistically significant difference between these two groups. (2) The bacterial eradication rates were 96.8%(31/32) vs 96.9%(30/31). There was no statistically significant difference between the two groups. (3) Drug-related adverse effects were 26.1%(18/69) in azithromycin group, higher than that in cefuroxime with or without erythromycin ethylsuccinate group 8.7%(6/69). This is due to more patients with local reactions in azithromycin group than those in cefuroxime with or without erythromycin ethylsuccinate group. These drug-related events could be alleviated by slowing down the speed of infusion; most of these adverse effects of both groups were mild and tolerable. Drug-related abnormal laboratory findings occurred in both groups were 21.7% (15/69), all were mild and transient. Conclusions:The clinical efficacy of azithromycin is as good as cefuroxime with or without erythromycin ethylsuccinate, furthermore, the duration of therapy is shorter in azithromycin group. The adverse reaction rates of azithromycin are higher than those of cefuroxime with or without erythromycin ethylsuccinate, however, most adverse reaction are mild and tolerable.